{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:27:19Z","timestamp":1785803239933,"version":"3.56.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Tuberc."],"abstract":"<jats:p>Major scientific advances across the tuberculosis research continuum emerged in 2025, offering new opportunities to accelerate progress toward global elimination. This review synthesizes developments in diagnosis, treatment, prevention, and post-disease care, highlighting innovations that broaden access, strengthen mechanistic insight, and expand the scope of actionable tools. Diagnostic progress included artificial intelligence\u2013enabled chest imaging, noninvasive molecular testing using tongue and stool samples, simple stool-based procedures suitable for decentralized settings, biomarkers that support treatment monitoring, low-complexity nucleic acid tests for extrapulmonary disease, and new point-of-care methods for detecting infection. Culture-free sequencing approaches further improved rapid identification of drug resistance. Therapeutic advances featured shorter all-oral regimens for drug-susceptible and rifampin-resistant disease, along with emerging compounds that target essential microbial pathways. Additional progress in host-directed therapies, vaccines, and nanoparticle-based drug delivery broadened preventive and therapeutic options. Conceptual developments challenged the validity of symptom-based disease categories and supported biologically grounded terminology, while consensus definitions for post-tuberculosis lung disease clarified the substantial long-term respiratory burden among survivors. Despite this momentum, health-system limitations and inequitable access continue to constrain real-world impact. Collectively, the scientific advances of 2025 were substantial and outline a clearer mechanistic and programmatic path toward tuberculosis elimination, but their success will depend on effective implementation and integration into routine care.<\/jats:p>","DOI":"10.3389\/ftubr.2026.1805962","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:02:58Z","timestamp":1779775378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Research overview\u20142025: integrating scientific progress to accelerate global tuberculosis elimination"],"prefix":"10.3389","volume":"4","author":[{"given":"Patrick K.","family":"Moonan","sequence":"first","affiliation":[{"name":"U.S. Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy H.","family":"Holtz","sequence":"additional","affiliation":[{"name":"Sumner M. Redstone Global Center for Prevention and Wellness, The George Washington University Milken Institute School of Public Health","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","volume-title":"Global Tuberculosis Report 2025","year":"2025"},{"key":"B2","volume-title":"The End TB Strategy","year":"2015"},{"key":"B3","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new End TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(24)02479-6","article-title":"Tuberculosis","volume":"405","author":"Trajman","year":"2025","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"ooae151","DOI":"10.1093\/jamiaopen\/ooae151","article-title":"Towards human-AI collaboration in radiology: a multidimensional evaluation of the acceptability of AI for chest radiograph analysis in supporting pulmonary tuberculosis diagnosis","volume":"8","author":"Hua","year":"2025","journal-title":"JAMIA Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0000894","DOI":"10.1371\/journal.pdig.0000894","article-title":"Implementation costs and cost-effectiveness of ultraportable chest x-ray with artificial intelligence in active case finding for tuberculosis in Nigeria","volume":"4","author":"Garg","year":"2025","journal-title":"PLOS Digit Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e69068","DOI":"10.2196\/69068","article-title":"Diagnostic performance of artificial intelligence\u2013based methods for tuberculosis detection: systematic review","volume":"27","author":"Hansun","year":"2025","journal-title":"J Med Internet Res"},{"key":"B9","volume-title":"Use of Computer-aided detection Software for tuberculosis Screening: WHO Policy Statement (ISBN: 978-92-4-011037-3)","year":"2025"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106517","DOI":"10.1016\/j.jinf.2025.106517","article-title":"Tongue swab-based molecular diagnostics for pulmonary tuberculosis and drug resistance in adults: a prospective multicenter diagnostic accuracy study","volume":"91","author":"Wang","year":"2025","journal-title":"J Infect"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2401493","DOI":"10.1183\/13993003.01493-2024","article-title":"Rapid quantitative PCR on tongue swabs for pulmonary tuberculosis in adults: a prospective multicentre study","volume":"65","author":"Wang","year":"2025","journal-title":"Eur Respir J"},{"key":"B12","author":"Ajide","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100963","DOI":"10.1016\/j.lanmic.2024.100963","article-title":"Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis","volume":"6","author":"Carratal\u00e0-Castro","year":"2025","journal-title":"Lancet Microbe"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0104025","DOI":"10.1128\/jcm.01040-25","article-title":"Evaluation of the simple one-step (SOS) stool method for Truenat MTB plus and Xpert MTB\/XDR assay","volume":"64","author":"Haas","year":"2025","journal-title":"J Clin Microbiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/cid\/ciaf289","article-title":"Stool processing methods for Xpert ultra testing in childhood tuberculosis: a prospective, multicountry accuracy study","volume":"82","author":"Jaganath","year":"2026","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"ofaf345","DOI":"10.1093\/ofid\/ofaf345","article-title":"Stool-based molecular tuberculosis treatment monitoring: a faster means for detecting persistent mycobacteria compared to phenotypic culture","volume":"12","author":"Adu Gyamfi","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B17","volume-title":"WHO operational Handbook on tuberculosis: Module 3: Diagnosis (ISBN: 978-92-4-011099-1)","year":"2025"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1004610","DOI":"10.1371\/journal.pmed.1004610","article-title":"Diagnostic accuracy of the WHO tuberculosis treatment decision algorithms for children with presumptive tuberculosis: an individual participant data meta-analysis","volume":"22","author":"Olbrich","year":"2025","journal-title":"PLoS Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1473-3099(24)00494-8","article-title":"Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study","volume":"25","author":"Olbrich","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/cid\/ciae273","article-title":"Enhanced tuberculosis diagnosis with computer-aided chest X-ray and urine lipoarabinomannan in adults with HIV admitted to hospital (CASTLE study): a cluster randomized trial","volume":"80","author":"Burke","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"CD012768","DOI":"10.1002\/14651858.CD012768.pub4","article-title":"Low-complexity automated nucleic acid amplification tests for extrapulmonary tuberculosis and rifampicin resistance in adults and adolescents","volume":"8","author":"Kohli","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B22","first-page":"ofag268","article-title":"Performance of TB antigen-based skin tests amongst healthcare workers \u2014 Sevagram, India, 2023\u20132024","volume-title":"Open Forum Infect Dis","author":"Shivkumar","year":"2026"},{"key":"B23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/inthealth\/ihae048","article-title":"Evaluating the cost-effectiveness of Cy-Tb for LTBI in India: a comprehensive economic modelling analysis","volume":"17","author":"Muniyandi","year":"2025","journal-title":"Int Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"ciaf561","DOI":"10.1093\/cid\/ciaf561","article-title":"Diagnostic accuracy of the STANDARD F TB-feron FIA assay for tuberculosis infection in Vietnam: a cross-sectional study","author":"Nguyen","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2402000","DOI":"10.1183\/13993003.02000-2024","article-title":"How to diagnose TB in migrants? A systematic review of reviews and decision tree analytical modelling exercise to evaluate properties for single and combined tuberculosis screening tests","volume":"66","author":"Zenner","year":"2025","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1473-3099(24)00586-3","article-title":"Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows","volume":"25","author":"Colman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1637254","DOI":"10.3389\/fmicb.2025.1637254","article-title":"Progress of anti-tuberculosis drug targets and novel therapeutic strategies","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Microbiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s40265-022-01817-w","article-title":"The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis","volume":"82","author":"Edwards","year":"2022","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMc1913327","article-title":"Telacebec (Q203), a new antituberculosis agent","volume":"382","author":"de Jager","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0154224","DOI":"10.1128\/aac.01542-24","article-title":"Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants","volume":"69","author":"Lombardi","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1093\/jac\/dkaf274","article-title":"Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology","volume":"80","author":"van Der Feltz","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"B32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41591-024-02829-7","article-title":"A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial","volume":"30","author":"Diacon","year":"2024","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2426827122","DOI":"10.1073\/pnas.2426827122","article-title":"Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity","volume":"122","author":"Fountain","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month rifapentine regimens with or without moxifloxacin for Tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3201\/eid3103.241634","article-title":"Efficacy and safety of 4-month rifapentine-based Tuberculosis treatments in persons with diabetes","volume":"31","author":"Kurbatova","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5588\/ijtld.24.0616","article-title":"Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen","volume":"29","author":"Galvis","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible Tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"B38","author":"Conradie","year":"2025"},{"key":"B39","volume-title":"WHO announces Landmark Changes in Treatment of Drug-resistant tuberculosis","year":"2025"},{"key":"B40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S2352-4642(24)00330-4","article-title":"Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis","volume":"9","author":"Garcia-Prats","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"EVIDoa2400190","DOI":"10.1056\/EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2025","journal-title":"NEJM Evid"},{"key":"B45","article-title":"Protecting households on exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx-MDR TB), ClinicalTrials.gov NCT03568383","author":"Churchyard","year":""},{"key":"B46","volume-title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (BREACH-TB)","author":"Nuermberger","year":""},{"key":"B47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/QCO.0000000000001156","article-title":"New drugs for the management of tuberculosis","volume":"38","author":"Cross","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/cid\/ciaf068","article-title":"Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: a multicentric retrospective cohort study","volume":"81","author":"Singla","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmi.2025.09.003","article-title":"High rates of acquired resistance to fluoroquinolones, bedaquiline, and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova","volume":"32","author":"Chesov","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"B50","first-page":"S573","article-title":"Safety and efficacy of TBAJ-876 in combination with pretomanid and linezolid: week 8 analysis result of NC-009","volume":"29","author":"Olugbosi","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/bcp.70333","article-title":"Population pharmacokinetics of TBAJ-587 and its main metabolites\u2013\u2013 evaluation of different loading dose strategies and early dose selection","volume":"92","author":"Leding","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1164\/rccm.202408-1632OC","article-title":"Telacebec, a potent agent in the fight against tuberculosis: findings from a randomized, phase 2 clinical trial and beyond","volume":"211","author":"Janssen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100952","DOI":"10.1016\/j.lanmic.2024.07.015","article-title":"Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b\/2a trial","volume":"6","author":"Heinrich","year":"2025","journal-title":"Lancet Microbe"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e00021-19","DOI":"10.1128\/AAC.00021-19","article-title":"Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of Tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary Tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant Tuberculosis disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2500315","DOI":"10.1183\/13993003.00315-2025","article-title":"Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"66","author":"Kwak","year":"2025","journal-title":"Eur Respir J"},{"key":"B58","article-title":"A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline","volume-title":"Combination with Pretomanid and Linezolid in Adult Participants with Newly Diagnosed, drug-sensitive, smear-positive Pulmonary Tuberculosis","author":"Olugosi","year":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v10i2.791","article-title":"A year in review on tuberculosis and non-tuberculous mycobacteria disease: a 2025 update for clinicians and scientists","volume":"10","author":"Lange","year":"2025","journal-title":"Pathog Immun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e1030","DOI":"10.1016\/S2214-109X(25)00046-4","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial","volume":"13","author":"Luabeya","year":"2025","journal-title":"Lancet Glob Health"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/S2352-3018(25)00124-9","article-title":"Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial","volume":"12","author":"Dagnew","year":"2025","journal-title":"Lancet HIV"},{"key":"B62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(24)00814-4","article-title":"Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"25","author":"Borges","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","article-title":"BCG Revaccination for the prevention of Mycobacterium tuberculosis infection","volume":"392","author":"Schmidt","year":"2025","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100922","DOI":"10.1016\/S2666-5247(24)00162-9","article-title":"Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study","volume":"6","author":"Hamilton","year":"2025","journal-title":"Lancet Microbe"},{"key":"B65","doi-asserted-by":"publisher","first-page":"100961","DOI":"10.1016\/j.lanmic.2024.100961","article-title":"Effectiveness of the primary Bacillus calmette-gu\u00e9rin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data","volume":"6","author":"Pelzer","year":"2025","journal-title":"Lancet Microbe"},{"key":"B66","doi-asserted-by":"publisher","first-page":"108233","DOI":"10.1016\/j.micpath.2025.108233","article-title":"Host-directed insights into mycobacterial infections: toward targeted immunomodulation","volume":"211","author":"Menon","year":"2025","journal-title":"Microb Pathog"},{"key":"B67","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/infdis\/jiaf510","article-title":"Tuberculosis biomarkers and host-directed therapy","volume":"233","author":"Collins","year":"2025","journal-title":"J Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"34310","DOI":"10.1038\/s41598-025-20188-2","article-title":"Dexamethasone inhibits Mycobacterium tuberculosis-induced glycolysis but preserves antimicrobial function in primary human macrophages","volume":"15","author":"Thong","year":"2025","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"100922","DOI":"10.1016\/S2666-5247(24)00162-9","article-title":"Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry Mendelian randomisation study","volume":"6","author":"Hamilton","year":"2025","journal-title":"Lancet Microbe"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1093\/cid\/ciaf611","article-title":"Reported tuberculosis symptoms: an inadequate classifier of disease state","volume":"82","author":"McCreesh","year":"2026","journal-title":"Clin Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"ciaf667","DOI":"10.1093\/cid\/ciaf667","article-title":"Why we should move away\u2014not towards\u2014symptom-based terminology and policy in tuberculosis","author":"Dale","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-025-02645-2","article-title":"Post-tuberculosis lung disease: a guide for clinicians","volume":"54","author":"Fumagalli","year":"2025","journal-title":"Infection"},{"key":"B73","doi-asserted-by":"publisher","first-page":"S1473-3099(25)00548-1","DOI":"10.1016\/S1473-3099(25)00548-1","article-title":"Post-tuberculosis lung disease: a case definition for use in research studies","author":"Bisson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/cid\/ciad730","article-title":"Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV","volume":"78","author":"Lin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1056\/NEJMoa2502866","article-title":"Trial of high-dose oral rifampin in adults with tuberculous meningitis","volume":"393","author":"Meya","year":"2025","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S1473-3099(25)00151-3","article-title":"Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial","volume":"25","author":"Paton","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S2352-3018(25)00002-5","article-title":"Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1\/2 trial","volume":"12","author":"Weld","year":"2025","journal-title":"Lancet HIV"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e016921","DOI":"10.1136\/bmjgh-2024-016921","article-title":"An evaluation of a choice architecture-based intervention on prescribing of TB preventive treatment to people living with HIV in Southern Africa (the CAT study): a cluster-randomised trial","volume":"10","author":"Shearer","year":"2025","journal-title":"BMJ Glob Health"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1093\/jac\/dkaf319","article-title":"Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study","volume":"80","author":"Gel\u00e9","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jama.2025.5180","article-title":"Long-acting HIV treatment in low- and middle-income countries: addressing the public health need","volume":"334","author":"Ehrenkranz","year":"2025","journal-title":"JAMA"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMp2415893","article-title":"An HIV vaccine in the era of twice-yearly lenacapavir for PrEP\u2014essential or irrelevant?","volume":"392","author":"Jatt","year":"2025","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14740338.2020.1694901","article-title":"Safety implications of combined antiretroviral and anti-tuberculosis drugs","volume":"19","author":"Cerrone","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B86","volume-title":"Operational Handbook on Tuberculosis","year":"2023"},{"key":"B87","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jctube.2016.02.001","article-title":"Mind the gap: time to address implementation gaps in tuberculosis diagnosis and treatment","volume":"6","author":"Pai","year":"2016","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0318123","DOI":"10.1371\/journal.pone.0318123","article-title":"Achieving the 95 95 95 targets for all: a pathway to ending AIDS","volume":"20","author":"Frescura","year":"2025","journal-title":"PLoS One"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e015868","DOI":"10.1136\/bmjgh-2024-015868","article-title":"Lessons learned from the COVID-19 pandemic: opportunities and challenges to leverage investments in HIV, tuberculosis and malaria for pandemic preparedness and response","volume":"10","author":"Tollefson","year":"2025","journal-title":"BMJ Glob Health"},{"key":"B90","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12992-025-01129-0","article-title":"Understanding the political economy of reforming global health initiatives\u2014insights from global and country levels","volume":"21","author":"Witter","year":"2025","journal-title":"Global Health"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.56021\/9781421437903","volume-title":"The Political Determinants of Health","author":"Dawes","year":"2020"},{"key":"B92","volume-title":"Infections and Inequalities: The Modern Plagues. Updated ed","author":"Farmer","year":"2001"}],"container-title":["Frontiers in Tuberculosis"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftubr.2026.1805962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:03:04Z","timestamp":1779775384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftubr.2026.1805962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":92,"alternative-id":["10.3389\/ftubr.2026.1805962"],"URL":"https:\/\/doi.org\/10.3389\/ftubr.2026.1805962","relation":{},"ISSN":["2813-7868"],"issn-type":[{"value":"2813-7868","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1805962"}}